Cancer Microarray, Genes and Proteins Laboratory, National Institute of Immunology, New Delhi, India.
Leuk Res. 2010 Jul;34(7):858-63. doi: 10.1016/j.leukres.2010.01.017. Epub 2010 Feb 6.
Early diagnosis and cure for patients with chronic myeloid leukemia (CML) exhibit significant clinical challenges because of the disease progression from chronic phase (CP) into a rapidly fatal blast crisis. Our earlier studies suggested an association of sperm associated antigen 9 (SPAG9) with various human malignancies. The present investigation revealed that SPAG9 mRNA and protein are expressed in CML patients (88%), in K562 and KCL-22 cells. Further, SPAG9 protein expression was also detected on cell surface suggesting that this molecule may be a suitable target for immunotherapy. Interestingly, 90% CML-CP patients showed humoral response against SPAG9, suggesting its important role in early diagnostic of CML-CP. Further investigation is warranted in establishing the potential of SPAG9 as a biomarker and immunotherapeutic target for early treatment of CML-CP patients.
早期诊断和治疗慢性髓性白血病(CML)患者具有显著的临床挑战,因为该疾病会从慢性期(CP)进展为快速致命的爆发危机。我们之前的研究表明,精子相关抗原 9(SPAG9)与各种人类恶性肿瘤有关。本研究显示,SPAG9mRNA 和蛋白在 CML 患者(88%)、K562 和 KCL-22 细胞中表达。此外,还在细胞表面检测到 SPAG9 蛋白表达,表明该分子可能是免疫治疗的合适靶点。有趣的是,90%的 CML-CP 患者对 SPAG9 表现出体液反应,表明其在 CML-CP 的早期诊断中具有重要作用。需要进一步研究以确定 SPAG9 作为 CML-CP 患者早期治疗的生物标志物和免疫治疗靶标的潜力。